Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by JEFFREY E GERSHENWALD and JEFFREY E LEE.
JEFFREY E GERSHENWALD
Connection Strength
1.957
JEFFREY E LEE
  1. Randomized controlled trial of a sun protection intervention for children of melanoma survivors. Cancer Epidemiol Biomarkers Prev. 2013 Oct; 22(10):1813-24.
    View in: PubMed
    Score: 0.115
  2. Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. J Clin Oncol. 2008 Sep 10; 26(26):4296-303.
    View in: PubMed
    Score: 0.080
  3. Melanoma adrenal metastasis: natural history and surgical management. Am J Surg. 2008 Mar; 195(3):363-8; discussion 368-9.
    View in: PubMed
    Score: 0.078
  4. Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma. Cancer. 2006 Dec 01; 107(11):2647-52.
    View in: PubMed
    Score: 0.072
  5. Assessment of the role of sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma. Cancer. 2006 Feb 15; 106(4):900-6.
    View in: PubMed
    Score: 0.068
  6. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol. 2005 Aug; 12(8):587-96.
    View in: PubMed
    Score: 0.065
  7. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol. 2003 Jun; 10(5):569-74.
    View in: PubMed
    Score: 0.056
  8. Implications of lymphatic drainage to unusual sentinel lymph node sites in patients with primary cutaneous melanoma. Cancer. 2002 Jul 15; 95(2):354-60.
    View in: PubMed
    Score: 0.053
  9. Presence of the human leukocyte antigen class II gene DRB1*1101 predicts interferon gamma levels and disease recurrence in melanoma patients. Ann Surg Oncol. 2002 Jul; 9(6):587-93.
    View in: PubMed
    Score: 0.053
  10. Significance of plasma cytokine levels in melanoma patients with histologically negative sentinel lymph nodes. Ann Surg Oncol. 2001 Mar; 8(2):116-22.
    View in: PubMed
    Score: 0.048
  11. How many lymph nodes are enough during sentinel lymphadenectomy for primary melanoma? Surgery. 2000 Aug; 128(2):306-11.
    View in: PubMed
    Score: 0.046
  12. Significance of multiple nodal basin drainage in truncal melanoma patients undergoing sentinel lymph node biopsy. Ann Surg Oncol. 2000 May; 7(4):256-61.
    View in: PubMed
    Score: 0.045
  13. Regional nodal basin control is not compromised by previous sentinel lymph node biopsy in patients with melanoma. Ann Surg Oncol. 2000 Apr; 7(3):226-31.
    View in: PubMed
    Score: 0.045
  14. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. Ann Surg Oncol. 2000 Mar; 7(2):160-5.
    View in: PubMed
    Score: 0.045
  15. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999 Mar; 17(3):976-83.
    View in: PubMed
    Score: 0.042
  16. Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. Surgery. 1998 Aug; 124(2):203-10.
    View in: PubMed
    Score: 0.040
  17. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol. 1998 Jun; 16(6):2253-60.
    View in: PubMed
    Score: 0.040
  18. Is surveillance imaging effective for detecting surgically treatable recurrences in patients with melanoma? A comparative analysis of stage-specific surveillance strategies. Ann Surg. 2014 Jun; 259(6):1215-22.
    View in: PubMed
    Score: 0.030
  19. Prospective assessment of lymphedema incidence and lymphedema-associated symptoms following lymph node surgery for melanoma. Melanoma Res. 2013 Aug; 23(4):290-7.
    View in: PubMed
    Score: 0.028
  20. Variants in melanocortin 1 receptor gene contribute to risk of melanoma--a direct sequencing analysis in a Texas population. Pigment Cell Melanoma Res. 2013 May; 26(3):422-5.
    View in: PubMed
    Score: 0.028
  21. Polymorphisms of nucleotide excision repair genes predict melanoma survival. J Invest Dermatol. 2013 Jul; 133(7):1813-21.
    View in: PubMed
    Score: 0.028
  22. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2012 Dec 15; 18(24):6758-70.
    View in: PubMed
    Score: 0.027
  23. Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review. Melanoma Res. 2012 Oct; 22(5):376-85.
    View in: PubMed
    Score: 0.027
  24. Influence of single nucleotide polymorphisms in the MMP1 promoter region on cutaneous melanoma progression. Melanoma Res. 2012 Apr; 22(2):169-75.
    View in: PubMed
    Score: 0.026
  25. Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Hum Mol Genet. 2011 Dec 15; 20(24):5012-23.
    View in: PubMed
    Score: 0.025
  26. Mapping FACT-melanoma quality-of-life scores to EQ-5D health utility weights. Value Health. 2011 Sep-Oct; 14(6):900-6.
    View in: PubMed
    Score: 0.025
  27. Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin Cancer Res. 2011 Jul 15; 17(14):4882-91.
    View in: PubMed
    Score: 0.024
  28. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst. 2011 Jan 19; 103(2):129-42.
    View in: PubMed
    Score: 0.024
  29. Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma. Eur J Cancer. 2011 Jan; 47(1):107-15.
    View in: PubMed
    Score: 0.023
  30. Conditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysis. Cancer. 2010 May 01; 116(9):2234-41.
    View in: PubMed
    Score: 0.023
  31. Conditional survival estimates improve over 5 years for melanoma survivors with node-positive disease. Ann Surg Oncol. 2010 Aug; 17(8):2015-23.
    View in: PubMed
    Score: 0.023
  32. Prospective assessment of postoperative complications and associated costs following inguinal lymph node dissection (ILND) in melanoma patients. Ann Surg Oncol. 2010 Oct; 17(10):2764-72.
    View in: PubMed
    Score: 0.023
  33. Lymph node ratio predicts disease-specific survival in melanoma patients. Cancer. 2009 Jun 01; 115(11):2505-13.
    View in: PubMed
    Score: 0.021
  34. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res. 2009 Feb; 19(1):42-9.
    View in: PubMed
    Score: 0.021
  35. Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma. Hum Mutat. 2008 Dec; 29(12):1443-51.
    View in: PubMed
    Score: 0.021
  36. Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys. 2009 Apr 01; 73(5):1376-82.
    View in: PubMed
    Score: 0.020
  37. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer. 2008 Sep 02; 99(5):734-40.
    View in: PubMed
    Score: 0.020
  38. Fibrin sealant does not decrease seroma output or time to drain removal following inguino-femoral lymph node dissection in melanoma patients: a randomized controlled trial (NCT00506311). World J Surg Oncol. 2008 Jun 18; 6:63.
    View in: PubMed
    Score: 0.020
  39. Prospective assessment of the reliability, validity, and sensitivity to change of the Functional Assessment of Cancer Therapy-Melanoma questionnaire. Cancer. 2008 May 15; 112(10):2249-57.
    View in: PubMed
    Score: 0.020
  40. Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease. Cancer. 2008 May 01; 112(9):2030-7.
    View in: PubMed
    Score: 0.020
  41. Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: a case-control study. Int J Cancer. 2008 May 01; 122(9):2077-84.
    View in: PubMed
    Score: 0.020
  42. Polymorphisms of TP53 Arg72Pro, but not p73 G4C14>A4TA4 and p21 Ser31Arg, contribute to risk of cutaneous melanoma. J Invest Dermatol. 2008 Jun; 128(6):1585-8.
    View in: PubMed
    Score: 0.019
  43. Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma. Ann Surg Oncol. 2007 Oct; 14(10):2867-75.
    View in: PubMed
    Score: 0.019
  44. Cost effectiveness of adjuvant interferon in node-positive melanoma. J Clin Oncol. 2007 Jun 10; 25(17):2442-8.
    View in: PubMed
    Score: 0.019
  45. Polymorphisms of the neuronal and inducible nitric oxide synthase genes and the risk of cutaneous melanoma: a case-control study. Cancer. 2007 Apr 15; 109(8):1570-8.
    View in: PubMed
    Score: 0.018
  46. Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: a case-control analysis. Cancer Epidemiol Biomarkers Prev. 2006 Dec; 15(12):2526-32.
    View in: PubMed
    Score: 0.018
  47. Ethnic differences among patients with cutaneous melanoma. Arch Intern Med. 2006 Sep 25; 166(17):1907-14.
    View in: PubMed
    Score: 0.018
  48. Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma. J Invest Dermatol. 2007 Feb; 127(2):276-80.
    View in: PubMed
    Score: 0.018
  49. Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma. J Clin Oncol. 2006 Jun 20; 24(18):2858-65.
    View in: PubMed
    Score: 0.017
  50. Invasive squamous cell carcinoma of the skin: defining a high-risk group. Ann Surg Oncol. 2006 Jul; 13(7):902-9.
    View in: PubMed
    Score: 0.017
  51. Metastatic melanoma to lymph nodes in patients with unknown primary sites. Cancer. 2006 May 01; 106(9):2012-20.
    View in: PubMed
    Score: 0.017
  52. Genetic variants of the ADPRT, XRCC1 and APE1 genes and risk of cutaneous melanoma. Carcinogenesis. 2006 Sep; 27(9):1894-901.
    View in: PubMed
    Score: 0.017
  53. Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Pharmacogenet Genomics. 2006 Apr; 16(4):253-63.
    View in: PubMed
    Score: 0.017
  54. In vitro sensitivity to ultraviolet B light and skin cancer risk: a case-control analysis. J Natl Cancer Inst. 2005 Dec 21; 97(24):1822-31.
    View in: PubMed
    Score: 0.017
  55. Combined-modality therapy for patients with regional nodal metastases from melanoma. Int J Radiat Oncol Biol Phys. 2006 Jan 01; 64(1):106-13.
    View in: PubMed
    Score: 0.016
  56. Population-based assessment of surgical treatment trends for patients with melanoma in the era of sentinel lymph node biopsy. J Clin Oncol. 2005 Sep 01; 23(25):6054-62.
    View in: PubMed
    Score: 0.016
  57. Melanoma metastatic to cervical lymph nodes: Can radiotherapy replace formal dissection after local excision of nodal disease? Head Neck. 2005 Aug; 27(8):718-21.
    View in: PubMed
    Score: 0.016
  58. A critical assessment of adjuvant radiotherapy for inguinal lymph node metastases from melanoma. Ann Surg Oncol. 2004 Dec; 11(12):1079-84.
    View in: PubMed
    Score: 0.016
  59. Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer. 2004 Apr 01; 100(7):1478-83.
    View in: PubMed
    Score: 0.015
  60. Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. Cancer. 2004 Jan 15; 100(2):383-9.
    View in: PubMed
    Score: 0.015
  61. p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma. J Invest Dermatol. 2003 Dec; 121(6):1510-4.
    View in: PubMed
    Score: 0.015
  62. Repair of UV light-induced DNA damage and risk of cutaneous malignant melanoma. J Natl Cancer Inst. 2003 Feb 19; 95(4):308-15.
    View in: PubMed
    Score: 0.014
  63. Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. J Clin Oncol. 2002 Dec 01; 20(23):4555-8.
    View in: PubMed
    Score: 0.014
  64. DNA repair gene XRCC3 241Met variant is not associated with risk of cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev. 2002 Oct; 11(10 Pt 1):1142-3.
    View in: PubMed
    Score: 0.013
  65. Adjuvant irradiation for axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys. 2002 Mar 15; 52(4):964-72.
    View in: PubMed
    Score: 0.013
  66. Surgical margins and prognostic factors in patients with thick (>4mm) primary melanoma. Ann Surg Oncol. 1998 Jun; 5(4):322-8.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.